[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2014DN08215A - - Google Patents

Download PDF

Info

Publication number
IN2014DN08215A
IN2014DN08215A IN8215DEN2014A IN2014DN08215A IN 2014DN08215 A IN2014DN08215 A IN 2014DN08215A IN 8215DEN2014 A IN8215DEN2014 A IN 8215DEN2014A IN 2014DN08215 A IN2014DN08215 A IN 2014DN08215A
Authority
IN
India
Prior art keywords
osteoclasts
pharmaceutical composition
antibody
inhibiting
gene
Prior art date
Application number
Inventor
Yoshiharu Hiruma
Takako Kimura
Hironari Shimizu
Original Assignee
Daiichi Sankyo Companyltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Companyltd filed Critical Daiichi Sankyo Companyltd
Publication of IN2014DN08215A publication Critical patent/IN2014DN08215A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

To provide an abnormal bone metabolism treatment and/or a prophylactic pharmaceutical composition targeting a protein coded for by a gene that is strongly expressed in osteoclasts. The provision etc. of a pharmaceutical composition containing an antibody that specifically recognizes human SIGLEC15 and exhibits the effect of inhibiting the formation of osteoclasts.
IN8215DEN2014 2012-03-30 2013-03-29 IN2014DN08215A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012078842 2012-03-30
PCT/JP2013/059654 WO2013147213A1 (en) 2012-03-30 2013-03-29 Anti-siglec15 antibody with modified cdr

Publications (1)

Publication Number Publication Date
IN2014DN08215A true IN2014DN08215A (en) 2015-05-15

Family

ID=49260454

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8215DEN2014 IN2014DN08215A (en) 2012-03-30 2013-03-29

Country Status (20)

Country Link
US (1) US9464133B2 (en)
EP (1) EP2832857B1 (en)
JP (1) JP6059205B2 (en)
KR (1) KR20150003170A (en)
CN (1) CN104334722A (en)
AU (1) AU2013241003A1 (en)
BR (1) BR112014024269A8 (en)
CA (1) CA2868959A1 (en)
ES (1) ES2660472T3 (en)
HK (1) HK1204657A1 (en)
IL (1) IL234883A0 (en)
IN (1) IN2014DN08215A (en)
MX (1) MX2014011828A (en)
NZ (1) NZ631509A (en)
PH (1) PH12014502187A1 (en)
RU (1) RU2014143798A (en)
SG (1) SG11201405966PA (en)
TW (1) TW201343672A (en)
WO (1) WO2013147213A1 (en)
ZA (1) ZA201407079B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JPWO2009048072A1 (en) 2007-10-11 2011-02-17 第一三共株式会社 Antibodies targeting the osteoclast-related protein Siglec-15
CN104507969A (en) 2012-07-19 2015-04-08 阿莱斯亚生物疗法股份有限公司 Anti-siglec-15 antibodies
EP3157562A4 (en) * 2014-06-18 2017-12-20 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
WO2018143336A1 (en) * 2017-02-03 2018-08-09 住友化学株式会社 Pancreatic cancer detection method
CN110913905A (en) 2017-06-30 2020-03-24 国立大学法人北海道大学 Therapeutic agent for infantile osteoporosis without growth disturbance
CN113817057B (en) * 2020-06-19 2024-02-20 盛禾(中国)生物制药有限公司 Anti-siglec 15 antibody and application thereof
TW202235436A (en) * 2021-02-23 2022-09-16 大陸商上海濟煜醫藥科技有限公司 Siglec-15 binding protein and preparation and use thereof
CN114957468A (en) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 anti-Siglec 15 antibody and application thereof
CN113577283A (en) * 2021-07-19 2021-11-02 河北医科大学第三医院 Application of Siglec-15 inhibitor in preparation of medicines for preventing and treating giant cell tumor of bone
CN118043351A (en) * 2021-08-31 2024-05-14 上海医药集团股份有限公司 Siglec 15-targeted antigen binding proteins and uses thereof
WO2023241538A1 (en) * 2022-06-13 2023-12-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-siglec15 antibodies and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE19653646A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Substituted purine derivatives, processes for their preparation, agents containing them and their use
CA2781623A1 (en) 1997-04-15 1998-10-22 Daiichi Sankyo Company, Limited Novel protein binding to osteoclastogenesis inhibitory factor and process for producing the same
ES2340112T3 (en) 1998-04-20 2010-05-28 Glycart Biotechnology Ag ANTIBODY GLICOSILATION ENGINEERING FOR THE IMPROVEMENT OF DEPENDENT CELLULAR CYTOTOXICITY OF ANTIBODIES.
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
KR100877676B1 (en) 2000-10-06 2009-01-09 교와 핫꼬 기린 가부시키가이샤 Cells producing antibody compositions
AU2002233994A1 (en) 2000-11-08 2002-05-21 Incyte Genomics, Inc. Secreted proteins
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
WO2002064771A1 (en) 2001-02-15 2002-08-22 Mochida Pharmaceutical Co., Ltd. Novel cell adhesion molecule specific to activated leukocyte
DE60235989D1 (en) 2001-06-26 2010-05-27 Amgen Fremont Inc ANTIBODIES AGAINST OPGL
EP1456655A2 (en) 2001-11-13 2004-09-15 Incyte Genomics, Inc. Receptors and membrane-associated proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
AU2004203727C1 (en) 2003-01-07 2008-08-21 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US7405037B2 (en) 2004-05-07 2008-07-29 Lonza Walkersville, Inc. Methods and tools for detecting collagen degradation
JP4604184B2 (en) 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 Novel sugar chain recognition protein and its gene
AU2007215334B2 (en) 2006-02-13 2013-11-21 Daiichi Sankyo Company, Limited Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JPWO2009048072A1 (en) 2007-10-11 2011-02-17 第一三共株式会社 Antibodies targeting the osteoclast-related protein Siglec-15
CN102272306B (en) * 2009-04-09 2017-12-26 第一三共株式会社 The anti-antibody of Siglec 15
AU2011313596A1 (en) 2010-10-05 2013-04-11 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein Siglec-15

Also Published As

Publication number Publication date
CN104334722A (en) 2015-02-04
HK1204657A1 (en) 2015-11-27
EP2832857B1 (en) 2018-01-03
MX2014011828A (en) 2014-12-10
US9464133B2 (en) 2016-10-11
ZA201407079B (en) 2016-02-24
JPWO2013147213A1 (en) 2015-12-14
ES2660472T3 (en) 2018-03-22
SG11201405966PA (en) 2014-11-27
KR20150003170A (en) 2015-01-08
BR112014024269A2 (en) 2017-06-20
RU2014143798A (en) 2016-05-27
BR112014024269A8 (en) 2017-07-25
US20150056189A1 (en) 2015-02-26
PH12014502187A1 (en) 2014-12-10
IL234883A0 (en) 2014-12-31
WO2013147213A1 (en) 2013-10-03
JP6059205B2 (en) 2017-01-11
TW201343672A (en) 2013-11-01
CA2868959A1 (en) 2013-10-03
EP2832857A4 (en) 2016-02-17
AU2013241003A1 (en) 2014-10-16
EP2832857A1 (en) 2015-02-04
NZ631509A (en) 2016-09-30

Similar Documents

Publication Publication Date Title
IN2014DN08215A (en)
MX343049B (en) ANTI-Siglec-15 ANTIBODY.
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
AP3847A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
MX356525B (en) Aav -vectors for use in gene therapy of choroideremia.
MX2015007921A (en) Novel heterocyclic compounds as bromodomain inhibitors.
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
MX348470B (en) Substituted annellated pyrimidine and the use thereof.
MX2015002371A (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same.
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
MY181828A (en) Bicyclically substituted uracils and the use therapy
MX337549B (en) Insulin derivatives containing additional disulfide bonds.
MY163257A (en) Humanised anti-cd52 antibodies
UA107204C2 (en) ANTI-FUNCTIONAL COMPOSITION CONTAINING THE PYTHIUM OLIGANDRUM Fungal Organism
MX2015008877A (en) Mixed disulfide conjugates of thienopyridine compounds and uses thereof.
IN2014DN08385A (en)
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX359181B (en) Collagen hydrolysate and use thereof.
IN2014DN03010A (en)
IN2014DN00123A (en)
UA115307C2 (en) APPLICATION OF MEDICINAL PRODUCT CONTAINING RECOMBINANT LECTIN MELINES FOR TREATMENT OF SKIN CANCER
NZ606186A (en) Use of lactoferrin to treat proteinuria
MX2015008454A (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders.
TR201200212A2 (en) Enhanced formulations containing risedronate.